Pancreatic cancer has a poor prognosis; hence, novel prognostic markers and effective therapeutic targets should be identified. We aimed to evaluate folate receptor alpha (FR-α) expression in pancreatic cancer and examine its association with clinicopathological features. We utilized tissue samples from 100 primary pancreatic cancer patients who underwent surgery. FR-α was expressed in 37 of 100 cases (37%). The FR-α-positive group (median, 18.8 months) had a significantly poorer prognosis than the FR-α-negative group [median 21.3 months; HR 1.89 (1.12-3.12); P = 0.017]. These groups were not significantly different regarding progression-free survival (P = 0.196). Furthermore, other serum tumor markers including CA19-9 (mean, 186 vs. 822 U/ml; P = 0.001), Dupan-2 (286 vs. 1133 U/ml; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml; P = 0.006) were significantly downregulated in the FR-α-positive group. CA19-9 was another prognostic factor, in addition to FR-α, and patient prognosis showed clear stratification curves with the expression of these two molecules. Along with CA19-9, FR-α expression was an independent prognostic factor for the overall survival. FR-α and CA19-9 helped predict patient prognosis based on stratification curves.
Introduction
Pancreatic cancer is one of the most difficult malignant neoplasms to treat and its incidence has increased worldwide; accordingly, its 5-year patient survival rate is extremely low, approximately 5-6% [1, 2] . Although the efficacy of multicombination chemotherapy including 5-FU or gemcitabine has recently been reported [3] [4] [5] , this does not typically result in complete remission, and surgical resection is the only curative therapy. Unfortunately, only 15-20% patients with pancreatic cancer can be treated surgically, and the 5-year survival rate for the operative cases is only approximately 20-40%, irrespective of postoperative adjuvant chemotherapy [1, 2, 5] . In unresectable cases, the median survival period is approximately 8-11 months, which is less than 1 year, with multi-drug combination therapy [2] .
Molecular targeted therapies have been developed for various tumors; however, to date, the only such agent that is available for pancreatic cancer treatment is erlotinib, which is an epidermal growth factor receptor tyrosine kinase inhibitor. However, when used in combination therapy with gemcitabine, this drug only extends patient survival by approximately 1-2 weeks [6] . Thus, novel therapeutic regimens are highly sought for this aggressive disease. Recently, a molecular agent targeting folate receptor α (FR-α) has been applied to patients with ovarian cancer that overexpresses FR-α [7] [8] [9] . Folate receptor alpha (FR-α) is a glycosylphosphatidylinositol (GPI)-anchored membrane protein; the intake of folate is required through this protein in rapidly proliferating cells for the one-carbon metabolic reaction and DNA biosynthesis, repair, and methylation [10] . Furthermore, it has been reported that FR-α contributes to cell proliferation through intracellular signaling including activation of the JAK-STAT3 pathway [7, 11] . Very low levels of FR-α are detected in normal tissues, whereas its obvious overexpression has been found in various tumor cells [7, 12, 13] .
Advancements in molecular medicine targeting FRα have advanced ovarian cancer treatment. Based on a phase III study including high doses, a regimen including farletuzumab, an anti-FR-α antibody, was shown to extend progression-free survival by approximately 1 month in certain subgroups [14] . From the database of the Cancer Cell Line Encyclopedia, it was reported that FRα is overexpressed in pancreatic cancer following breast cancer incidence, at the mRNA level [15] ; however, the frequency of this event and its significance have not been clarified. In the present study, we analyzed the expression of FR-α and its clinicopathologic significance in resectable pancreatic cancer.
Materials and methods

Patient selection
In Okayama University and its related hospitals, 100 patients with primary pancreatic cancer who underwent surgery from December 2002 to December 2014 were enlisted. Regarding tissue type, adenocarcinoma and papillary mucinous adenocarcinoma of the pancreatic duct were examined, and rare tissue types were excluded. Clinical, laboratory, imaging, and pathological findings were extracted from their medical records. Tumor stage was evaluated in accordance with the American Joint Committee on Cancer (AJCC) TNM system [16] . The study protocol was approved by the Institutional Review Board of Okayama University (no. 1603-011, Okayama, Japan). All study procedures were performed in accordance with guidelines of the Declaration of Helsinki. Immunohistological examination was carried out using a Folate Receptor alpha IHC Assay Kit and a mouse antihuman folate receptor alpha monoclonal antibody [26 B 3. F 2] (Biocare Medical, Concord, CA, USA) was applied to formalin-fixed and paraffin-embedded materials.
Evaluation of immunostaining was performed by two expert pathologists (K.T, T.T). Lung cancer tissues, previously confirmed to be positive for FRα, were simultaneously stained and used as a positive control.
When cell membrane and/or cytoplasmic staining was identified in ≥ 30% of tumor cells, the specimen was determined to be positive for FRα (Fig. 1) . Regarding the determination of the cutoff value for FR-α, we preliminarily evaluated the relation between some positive percentages and patient prognosis; this value was determined to be 30% (Supplementary Table 1 ).
Statistical analysis
Statistical analysis was performed using SPSS statistics 24 for Windows (SPSS Inc., Chicago, IL, USA). Qualitative variables were compared by performing Chi-square or Fisher's tests; quantitative variables were compared by performing a Student's t test or a nonparametric (Wilcoxon) test, whereas a Kruskal-Wallis rank test was used for comparisons among multiple groups. Survival analysis was performed by Kaplan-Meier analysis and log-rank tests. Cox regression analysis was used for multivariate survival analysis. P values less than 0.05 were considered statistically significant.
Results
Patients and clinicopathological data
Data were obtained from 100 pancreatic cancer specimens that had been examined thoroughly before surgery, and these cases were expected to be controllable. These 100 patients included 57 men and 43 women. The tumor location was the pancreatic head for 77 cases, pancreatic body for 14 cases, and the pancreatic tail for 9 cases, and the mean tumor size was 30 mm. Histologically, complete resection was achieved in 95 cases, and in the remaining five cases, tumors were observed in the resected stump. Distant metastasis was detected in seven cases, with five cases exhibiting metastases to regional lymph nodes, and two cases exhibiting liver metastases. Postoperative adjuvant chemotherapy was administered to 87 patients. Preoperative chemotherapy was administered to five patients, who were suspected to have disease that invaded the celiac trunk of the celiac artery or the superior mesenteric artery. In these five cases, the tumor was downstaged via chemotherapy, and no infiltration into the trunk of the celiac artery or the superior mesenteric artery was observed in any of the cases during surgery. Regarding the average values from blood analyses (from all 100 cases), a high level of the hepatobiliary enzyme was observed with AST levels of 57 IU/l, ALT levels of 73.1 IU/l, ALP levels of 527.6 IU/l, and T. Bil levels of 2.1 mg/dl. In addition, high levels of tumor markers were observed, with CEA levels of 22.6 ng/ml, CA19-9 levels of 587 U/ml, DUPAN2 levels of 804 U/ml, and SPan1 levels of 134 U/ml. Histologically, ductal adenocarcinoma comprised 89 cases and intraductal papillary mucinous neoplasm with associated invasive carcinoma comprised 11 cases. Regarding the degree of differentiation, 40 cases were of the welldifferentiated type, 37 were of the moderately differentiated type, and 12 were of the poorly differentiated type.
Immunostaining for FR-α
FR-α was expressed in 37 of 100 cases (37%). FR-α expression was not associated with the histologic type (P = 0.086). However, even in tissues from the same case, staining intensity was sometimes observed to differ depending on the location; thus, this staining pattern, considered tumor heterogeneity, was observed.
Association between FRα expression and clinicopathologic factors
Based on FR-α expression, stratification and analysis were performed. Clinical and pathological features are summarized in Tables 1 and 2 . On comparing the FR-α-positive group with the group showing low expression, serum tumor markers such as CA19-9 (186 vs. 822 U/ml, respectively; P = 0.001), Dupan-2 (286 U/ml vs. 1133 U/ml, respectively; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml, respectively; P = 0.006) were significantly downregulated. In contrast, a significant difference was not found with CEA (13.9 vs. 27.8 ng/ml, respectively; P = 0.3; Table 1 ). Regarding age, sex, tumor diameter, tumor localization, preoperative or postoperative chemotherapy, blood parameters other than tumor markers, distant metastasis, and tumor remnants after surgery, there were no statistically significant differences between the groups (Table 1 ). In addition, a significant difference was not observed between the groups with respect to histologic type, degree of differentiation, blood vessels emanating from the pancreas, and invasion into a nerve plexus (Table 2) .
Prognostic significance of FR-α
Regarding overall survival (OS), the FR-α-positive group (median, 18.8 months) had significantly poorer prognosis than the FR-α-negative group (median, 21.3 months; HR 1.89 (1.12-3.12); P = 0.017). In contrast, regarding progression-free survival (PFS), there was no significant difference between the groups (P = 0.196; Fig. 2 ). In addition, based on the investigation of factors contributing to OS, FR-α expression, advanced pT stage or pN stage, the presence of distant metastasis, and high CA 19-9 levels were poor prognostic factors based on univariate analysis. Further multivariate analysis revealed that FR-α expression, advanced pN stage, and high CA 19-9 levels were independent prognostic factors (Table 3) .
Depending on high or low serum CA 19-9 levels (≥ 500 vs < 499 U/ml) and FR-α positivity or negativity, 96 cases that had been examined for CA19-9 serum levels were stratified into four groups, as shown in Table 4 , and the OS and PFS were examined (Fig. 3) . Statistically significant differences were observed in both OS and relapse-free survival. The average of CA19-9 value was 186 IU/ml in the FR-α negative group and 822 IU/ml in the FR-α positive group. Therefore, 500 IU/ml which is the average value of these was determined as cutoff value.
Discussion
We examined 100 surgically resected pancreatic cancer specimens, including 95 cases in which histologically curative resection was achieved and 87 patients who received postoperative adjuvant chemotherapy. However, the 5-year survival rate was only 22%, concurrent with previous reports. Interestingly, the OS of patients in the FR-α-positive group was significantly longer than that in the negative group. Although the PFS rates of these two groups were slightly but not significantly similar to the OS rates. The discrepancy between OS and PFS in the FR-α-positive and -negative groups was not clearly resolved; however, the patients experiencing relapse were treated with chemotherapies, and response to such therapies might be different between the two groups. This should be clarified in future studies. Furthermore, this study included some patients who underwent preoperative chemotherapy. This may have somewhat affected FR-α expression in tumor cells. This constitutes a limitation of the present study.
To our knowledge, this is the first report focusing on FR-α in pancreatic cancer with specific reference to clinicopathological data. Similar conclusions have been made for ovarian [8, 9] and breast [12] cancer. FR-α expression was not only related to clinicopathological characteristics of the tumor, but was also expected to be a potential target for biomolecular treatment [7] . In ovarian cancer, a Phase III trial, wherein a regimen including farletuzumab, a humanized monoclonal antibody targeting FR-α, was followed to verify the combined effect of multiple drugs on recurrent disease. In this trial, the primary endpoint of improved PFS was not met; however, subsequent analysis suggested improved PFS in some patient subgroups administered higher doses, and in those with lower CA125 levels [14] .
Subsequently, in the poorly differentiated histological type, the presence of metastasis to regional lymph nodes and high levels of serum CA19-9 (> 500 IU/ml) were also independent prognostic factors. In general, serum CA19-9 levels correlate with large tumor volumes [17] . In addition, serum CA19-9 levels are also related to low tumor differentiation. In normal tissue such as the bile duct and pancreatic duct, CA 19-9 is present in the luminal membrane of mucosal epithelial cells. In contrast, in adenocarcinoma, this localization is not observed, and CA 19-9 is present in the cytoplasm and on the basement membrane side. Therefore, CA19-9 is secreted into blood vessels, and this tendency becomes more apparent with poor differentiation [18, 19] . Table 4 FR-α-positive status and serum CA19-9 levels A total of 97 cases, which had been examined for serum CA19-9 levels, were stratified into four groups based on high or low serum CA19-9 levels (≥ 500 vs < 499 U/ml) and FR-α-positive status CA19-9 high CA19-9 low
Interestingly, FR-α positivity and CA19-9 were closely related to patient prognosis; the FR-α-positive group showed poorer prognosis than the FR-α-negative group, and high CA19-9 levels were also indicative of a poor prognosis. Unexpectedly, the FRα-positive group comprised a group with low CA19-9 levels, and vice versa. In addition, in our series, DUPAN-2 and Span-1, which are commonly used as tumor markers for pancreatic cancer (such as CA19-9) and are positive in the Lewis negative phenotype in which CA19-9 is false negative [20, 21] , also yielded a negative association with FRα expression.
Previously, CA19-9 and other tumor markers have been reported as prognostic factors, whereas the current findings suggest that FRα could prove to be an additional prognostic factor. It was revealed that stratification using both indicators, FR-α and serum CA 19-9 levels, is more useful for predicting the prognosis of pancreatic cancer. As shown from the data, we could have subdivided into four groups, and patients' prognosis was correlated to these grouping.
In this study, we analyzed FRα expression and its association with clinicopathological features in pancreatic cancer and revealed that FR-α expression is an independent prognostic factor. Furthermore, FRα and CA19-9 could predict patient prognosis based on stratification curves. To our knowledge, this is the first report that clearly shows the stratification of patients with pancreatic cancer. In future studies, further accumulation of data and the development of an effective treatment approach for FRα-positive pancreatic cancer are expected.
